MGNX MacroGenics Inc.

15.92
+0.05  (+0%)
Previous Close 15.87
Open 15.8
Price To Book 2.42
Market Cap 776,985,470
Shares 48,805,620
Volume 211,460
Short Ratio
Av. Daily Volume 875,741

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data due 2H 2019.
Flotetuzumab
AML/MDS
BLA filing due 2H 2019.
Margetuximab SOPHIA study
Metastatic breast cancer
Phase 2/3 trial to be initiated 2H 2019.
Margetuximab in combination with pembrolizumab
Gastric cancer
Phase 2 trial to be initiated 2H 2019.
Enoblituzumab and MGA012
Solid tumors
Phase 1 partial clinical hold lifted January 25, 2019.
MGD009
Solid tumors
Phase 1 data due 2H 2019.
MGD013
Solid tumors
Phase 1 trial initiated 4Q 2018.
MGD019
Solid tumors

Latest News

  1. The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
  2. MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
  3. Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
  4. 2 Small Biotechs With Sagging Shares but Promising Prospects
  5. Implied Volatility Surging for MacroGenics (MGNX) Stock Options
  6. MacroGenics to Participate in Jefferies Healthcare Conference
  7. MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
  8. 3 Cancer Treatment Stocks to Buy Right Now
  9. Is MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Overpaid Relative To Its Peers?
  10. Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
  11. Why MacroGenics, Inc. Stock Is Heating Up Today
  12. The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics
  13. Microsoft, Amazon, and More: Why These Stocks Are Trending
  14. MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
  15. 3 Stocks With Big News Coming at ASCO 2019
  16. Edited Transcript of MGNX earnings conference call or presentation 26-Feb-19 9:30pm GMT
  17. Macrogenics Inc (MGNX) Q1 2019 Earnings Call Transcript
  18. MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
  19. MacroGenics: 1Q Earnings Snapshot
  20. MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results